RG7834
Based on 10 publication(s) in Google Scholar
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.29%
- CAS No.: 2072057-17-9
- Formule: C22H27NO6
- Masse moléculaire:401.45
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) RG7834
More- Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2316734121. [Abstract]
- Emerg Microbes Infect. 2021 Dec;10(1):37-50. [Abstract]
- PLoS Pathog. 2026 May 11;22(5):e1014213. [Abstract]
- Antiviral Res. 2025 May:237:106145. [Abstract]
- Antiviral Res. 2024 Jun:226:105888. [Abstract]
- Microbiol Spectr. 2026 Apr 7;14(4):e0263825. [Abstract]
- J Virol. 2025 Oct 10:e0092225. [Abstract]
- ACS Med Chem Lett. 2021 Jun 22;12(7):1130-1136. [Abstract]
- University of Colorado Denver. 2024.
- Research Square Preprint. 2022 May.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
WB
-
RT-PCR
Activité biologique
IC50: 2.8 nM (HBsAg), 2.6 nM (HBeAg), 3.2 nM (HBV DNA)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 2.2.15 | CC50 |
>10 μM
Compound: 1; RG-7834
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay
|
[PMID: 34267883] |
| HepG2 2.2.15 | CC50 |
>50 μM
Compound: (S)-64; RG7834
|
Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay
|
[PMID: 30286292] |
| HepG2 2.2.15 | EC50 |
1.2 nM
Compound: RG7834
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
|
[PMID: 38190324] |
| HepG2 2.2.15 | IC50 |
0.001 μM
Compound: 1; RG7834
|
Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA
Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA
|
[PMID: 38428537] |
RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells[1].
RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or hERG channel[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HBV-infected human liver chimeric uPA-SCID mice[1]
-
Dosage:4 mg/kg
-
Administration:Twice daily for 21 days
-
Result:Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2072057-17-9
-
Appearance Solid
-
Masse moléculaire 401.45
-
Formule C22H27NO6
-
Color Light yellow to yellow
-
SMILES
O=C(O)C1=CN2[C@@H](CC3=CC(OCCCOC)=C(C=C3C2=CC1=O)OC)C(C)C
-
Synonyms
RO 7020322; (S)-RO0321
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
2024 Jun 4;121(23):e2316734121. PMID: 38805292
RG7834 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2316734121. [Abstract]
TENT4 inhibitor, RG7834 (1 μM; 1 h), impairs liquid-to-solid phase transition of Amyloid bodies. Numbers denote percentage of cells with intranucleolar foci.
-
Emerg Microbes Infect
Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. [Abstract]2021 Dec;10(1):37-50. PMID: 33296295 -
PLoS Pathog
Host species-specific mutations in the thumb domain of the 3Dpol polymerase are required for efficient replication of human hepatitis A virus in mice. [Abstract]2026 May 11;22(5):e1014213. PMID: 42113844 -
Antiviral Res
Hepato-selective dihydroquinolizinones active against hepatitis A virus in vitro and in vivo. [Abstract]2025 May:237:106145. PMID: 40118118 -
Antiviral Res
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity. [Abstract]2024 Jun:226:105888. PMID: 38641024 -
Microbiol Spectr
A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection. [Abstract]2026 Apr 7;14(4):e0263825. PMID: 41810956 -
J Virol
2025 Oct 10:e0092225. PMID: 41070966
RG7834 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Oct 10:e0092225. [Abstract]
Activation of HBV-RADARS corresponds to its target HBV RNA levels in HepG2.2.15. The results showed that treating cells with the HBV RNA destabilizing compound RG7834 (1 μM) (except for HBx mRNA) significantly reduced total HBV RNA and antigen expression, corresponding with a decrease in HBV RNA-mediated Gluc activation from the HBV-RADARS reporter.
-
ACS Med Chem Lett
2021 Jun 22;12(7):1130-1136. PMID: 34267883 -
-
RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.
Telomere lengths determined by Southern blot TRF analysis of gDNA prepared from WT_iPSC_F and R449G_iPSC_1 treated with RG7834 (1 μM), Cordycepin, or DMSO. The results showed that RG7834 partially restored telomere length in R449G_iPSC_1 (lanes 7).
RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.
Total RNA prepared from WT_iPSC_F and R449G_iPSC_1 cells treated with RG7834 (1 μM), Cordycepin, or DMSO was subjected to qRT–PCR for oligoadenylated hTR. Bar graph of the mean fold change relative to DMSO-treated samples and normalized to GAPDH, ATP5b, and HPRT. The results showed that RG7834 (1 μM) led to a decrease in the proportion of oligoadenylated hTR.
Solvant et solubilité
DMSO : 125 mg/mL (311.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4910 mL | 12.4549 mL | 24.9097 mL | 62.2743 mL |
| 5 mM | 0.4982 mL | 2.4910 mL | 4.9819 mL | 12.4549 mL | |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4910 mL | 6.2274 mL | |
| 15 mM | 0.1661 mL | 0.8303 mL | 1.6606 mL | 4.1516 mL | |
| 20 mM | 0.1245 mL | 0.6227 mL | 1.2455 mL | 3.1137 mL | |
| 25 mM | 0.0996 mL | 0.4982 mL | 0.9964 mL | 2.4910 mL | |
| 30 mM | 0.0830 mL | 0.4152 mL | 0.8303 mL | 2.0758 mL | |
| 40 mM | 0.0623 mL | 0.3114 mL | 0.6227 mL | 1.5569 mL | |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4982 mL | 1.2455 mL | |
| 60 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0379 mL | |
| 80 mM | 0.0311 mL | 0.1557 mL | 0.3114 mL | 0.7784 mL | |
| 100 mM | 0.0249 mL | 0.1245 mL | 0.2491 mL | 0.6227 mL |
RG7834 Related Classifications
HY-117650A Related Classifications
Powered by Bioz